IP Library Granted Patent US 9,110,051
Granted Patent B2
US 9,110,051 · App. 13/594,564 · Granted Aug 18, 2015

Pharmacologic method of lowering cholesterol production

Inventors: Yvonne Lange (Chicago, IL); Theodore L. Steck (Chicago, IL)
Assignees: The University of Chicago; Rush University Medical Center
G01N33/5014G01N33/502G01N33/5008G01N33/5044G01N33/80G01N33/92G01N2800/044
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,110,051
App. No.
13/594,564
Granted
Aug 18, 2015
Kind
B2
Abstract

The present invention provides a screening method for identifying test agents that modulate cell membrane cholesterol activity. The modulating activity of the test agents may be measured using lytic compounds, which cause cell lysis or increases in cell permeability in response to cell membrane cholesterol levels. The invention further provides therapeutic agents that are identified using the screening method. The therapeutic agents either increase or decrease the cell membrane cholesterol activity, cholesterol concentration and/or both in vivo and/or in vitro.

Claims (18)

1. A method of screening compounds for cholesterol modulating activity, comprising:

(a) providing an array that comprises two or more samples of the same type of cell in vitro under physiological conditions;

(b) contacting one or more test agents with the cells;

(c) determining whether the one or more test agents increase cholesterol activity in the plasma membrane of the cells; and

(d) selecting those test agents that increase cholesterol activity, and determining if the selected test agents reduce HMG-CoA reductase and LDL receptor levels in cultured cells of the same cell type as the cells of steps (a)-(c).

2. The method of claim 1 , wherein (c) comprises contacting the cells with lytic compound, wherein the lytic compound causes perforation or lyses of the membrane of the cells when the cholesterol activity of the membrane of the one or more cells reaches a level at or above a threshold cholesterol level.

3. The method of claim 2 , wherein the lytic compound comprises a polyene antibiotic.

4. The method of claim 2 , wherein the lytic compound comprises a lysophosphatide or cholesterol oxidase.

5. The method of claim 2 , wherein the lytic compound comprises a bacterial toxin.

6. The method of claim 1 , further comprising performing (b) and (c) one or more times with different test agents.

7. The method of claim 6 , wherein the different test agents are screened simultaneously.

8. The method of claim 1 , wherein the cells comprise one or more eukaryotic cells.

9. The method of claim 8 , wherein the one or more eukaryotic cells comprise one or more mammalian cells.

10. The method of claim 8 , wherein the one or more cells comprise one or more red blood cells.

11. The method of claim 8 , wherein the one or more cells comprise one or more fibroblasts.

12. The method of claim 8 , wherein the one or more cells comprise one or more human cells.

13. The method of claim 1 , wherein the one or more cells have vigorous cholesterol homeostasis.

14. The method of claim 1 , wherein (c) comprises measuring the permeability of the membrane of the one or more cells or the turbidity of the one or more cells.

Assignments (3)
CONFIRMATORY LICENSE Recorded Apr 21, 2015
From: RUSH UNIVERSITY MEDICAL CENTER
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 035467/0111 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 17, 2014
From: STECK, THEODORE L.
To: THE UNIVERSITY OF CHICAGO
Reel/Frame 031991/0293 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 14, 2014
From: LANGE, YVONNE
To: RUSH UNIVERSITY MEDICAL CENTER
Reel/Frame 031957/0670 →
Continuity (3)
Division 10599898
Provisional Application 60561585 · Apr 13, 2004
Related Publication 20120322091A1 · Dec 20, 2012